Search Results - Sive, Jonathan

Transcriptional network control of normal and leukaemic haematopoiesis by Sive, Jonathan I., Göttgens, Berthold

Get full text Get full text Get full text

High rates of venous and arterial thrombotic events in patients with POEMS syndrome: results from the UCLH (UK) POEMS Registry by Sayar, Zara, Weatherill, Anna, Keddie, Stephen, Sive, Jonathan, Lunn, Michael P., Thomas, Mari, D’Sa, Shirley

Get full text Get full text Get full text

Real‐world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID‐19 disease) in patients with multiple myeloma receiv... by Cook, Gordon, John Ashcroft, A, Pratt, Guy, Popat, Rakesh, Ramasamy, Karthik, Kaiser, Martin, Jenner, Matthew, Henshaw, Sarah, Hall, Rachel, Sive, Jonathan, Stern, Simon, Streetly, Matthew, Bygrave, Ceri, Soutar, Richard, Rabin, Neil, Jackson, Graham H

Get full text Get full text Get full text

Outcomes In Older Adults with Acute Lymphoblastic Leukemia (ALL): Results From the International MRC UKALL XII/ECOG2993 Trial by Sive, Jonathan I., Buck, Georgina, Fielding, Adele, Lazarus, Hillard M., Litzow, Mark R., Luger, Selina, Marks, David I., McMillan, Andrew, Moorman, Anthony V., Richards, Susan M., Rowe, Jacob M., Tallman, Martin S., Goldstone, Anthony H.

Get full text Get full text Get full text

Defining Unmet Need Following Lenalidomide Refractoriness: Real-World Evidence of Outcomes in Patients With Multiple Myeloma by Lecat, Catherine S. Y., Taube, Jessica B., Wilson, William, Carmichael, Jonathan, Parrish, Christopher, Wallis, Gabriel, Kyriakou, Charalampia, Lee, Lydia, Mahmood, Shameem, Papanikolaou, Xenofon, Rabin, Neil K., Sive, Jonathan, Wechalekar, Ashutosh D., Yong, Kwee, Cook, Gordon, Popat, Rakesh

Get full text Get full text Get full text

COVID‐19 and myeloma clinical research – experience from the CARDAMON clinical trial by Camilleri, Marquita, Sive, Jonathan, Wilson, William, Pang, Gavin, Jenner, Richard, Phillips, Elizabeth, Popat, Rakesh, Ramasamy, Karthik, Bygrave, Ceri, Dadaga, Tushhar, Streetly, Matthew, Cavenagh, James, Chapman, Mike, Barrington, Sally, Pike, Lucy, Owen, Roger, Clifton‐Hadley, Laura, Yong, Kwee

Get full text Get full text Get full text

The impact of COVID-19 on autologous stem cell transplantation in multiple myeloma: A single-centre, qualitative evaluation study by Camilleri, Marquita, Bekris, Georgios, Sidhu, Govundeep, Buck, Caroline, Elsden, Esma, McCourt, Orla, Horder, Jackie, Newrick, Fiona, Lecat, Catherine, Sive, Jonathan, Papanikolaou, Xenofon, Popat, Rakesh, Lee, Lydia, Xu, Ke, Kyriakou, Charalampia, Rabin, Neil, Yong, Kwee, Fisher, Abigail

Get full text Get full text Get full text

Development of antibody response to SARS‐CoV‐2 following asymptomatic infection in patients with plasma cell disorders on immunomodulatory therapy by Chan, Wei Yee, Sanchez, Emilie, Chavda, Selina J., Lecat, Catherine S. Y., Ainley, Louise, Xu, Ke, Wisniowski, Brendan, Mahmood, Shameem, Papanikolaou, Xenofon, Kyriakou, Charalampia, Sive, Jonathan, Wechalekar, Ashutosh, Popat, Rakesh, Rabin, Neil, Lee, Lydia, Nastouli, Eleni, Yong, Kwee L.

Get full text Get full text Get full text

OAB-047: Plasma cell disorder patients are left vulnerable after one dose of the BNT162b2 mRNA or the ChAdOx-nCOV-19 COVID-19 vaccines by Chan, Wei Yee, Howells, Lara, Wilson, William, Sanchez, Emilie, Ainley, Louise, Chavda, Selina, Dowling, Emma, Correia, Nuno, Lecat, Catherine, McMillan, Annabel, Wisniowski, Brendan, Mahmood, Shameem, Papanikolaou, Xenofon, Lee, Lydia, Sive, Jonathan, Kyriakou, Charalampia, Wechalekar, Ashutosh, Popat, Rakesh, Rabin, Neil, Nastouli, Eleni, Yong, Kwee, Xu, Ke

Get full text Get full text

Serological response to the BNT162b2 mRNA or ChAdOx1 nCoV‐19 COVID‐19 vaccine after first and second doses in patients with plasma cell disorders: influence of host and disease fac... by Chan, Wei Yee, Howells, Lara, Wilson, William, Sanchez, Emilie, Ainley, Louise, Chavda, Selina J., Dowling, Emma, Correia, Nuno, Lecat, Catherine S. Y., McMillan, Annabel, Wisniowski, Brendan, Mahmood, Shameem, Papanikolaou, Xenofon, Lee, Lydia, Sive, Jonathan, Kyriakou, Charalampia, Wechalekar, Ashutosh, Popat, Rakesh, Rabin, Neil, Nastouli, Eleni, Yong, Kwee L., Xu, Ke

Get full text Get full text Get full text

Serological Response to the BNT162b2 mRNA or Chadox-Ncov-19 COVID-19 Vaccine after First and Second Doses in Plasma Cell Disorder Patients: Influence of Host and Disease Factors by Chan, Wei Yee, Howells, Lara, Wilson, William, Sanchez, Emilie, Ainley, Louise, Chavda, Selina J, Dowling, Emma, Correia, Nuno, Lecat, Catherine SY, McMillan, Annabel, Wisniowski, Brendan, Mahmood, Shameem, Papanikolaou, Xenofon, Lee, Lydia, Sive, Jonathan, Kyriakou, Charalampia, Wechalekar, Ashutosh D., Popat, Rakesh, Rabin, Neil K, Nastouli, Eleni, Yong, Kwee, Xu, Ke

Get full text Get full text

RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature by Chapman, Michael A., Sive, Jonathan, Ambrose, John, Roddie, Claire, Counsell, Nicholas, Lach, Anna, Abbasian, Mahnaz, Popat, Rakesh, Cavenagh, Jamie D., Oakervee, Heather, Streetly, Matthew J., Schey, Stephen, Koh, Mickey, Willis, Fenella, Virchis, Andres E., Crowe, Josephine, Quinn, Michael F., Cook, Gordon, Crawley, Charles R., Pratt, Guy, Cook, Mark, Braganza, Nivette, Adedayo, Toyin, Smith, Paul, Clifton-Hadley, Laura, Owen, Roger G., Sonneveld, Pieter, Keats, Jonathan J., Herrero, Javier, Yong, Kwee

Get full text Get full text Get full text